CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.
Exhibit 10.33
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.
|
Bio-Rad | Diagnostics Group | ||
| Laboratories | 0000 Xxxxxx Xxxxx Xxxxx | |||
| Xxxxxxxx, XX 00000 | ||||
| Phone: 0-0000XXXXXX (0-000-000-0000) | ||||
| Fax: 0-000-000-0000 | ||||
| Email: xxxxxxxx@xxx-xxx.xxx | ||||
| CONFIDENTIAL | ||||
PRICE AGREEMENT #20-28629
| Xxxx Xxxxxxx | Xxxxx Xxxx | |||
| BioDesix, Inc. | C/O BioDesix, Inc | |||
| 0000 Xxxxxxxxxx Xxxxx, Xxx. 000 | 0000 Xxxxxxxx Xxxxx, Xxxx. 0 | |||
| Xxxxxxx, XX 00000 | De Xxxx, XX 00000 | |||
| Xxxx-To Account: [***] | Ship-To Account: [***] |
Date: May 12, 2020
| Our Reference: | Xxxxx Xxxxx, Executive Account Manager Xxxxx Xxxxxxxx, Core Lab Immunochemistry Manager |
| Route: Best Way
Terms: Net 30 days from date of invoice
Any terms and conditions contained in Customer’s purchase or order form shall be null and void unless specifically agreed |
Shipment can be made 30 - 90 days for instrument and 3 - 5 days for reagents after receipt of order.
NOTE: Bio-Rad will only ship to end-user. Pricing to in writing by Bio-Rad. quoted to United States and its possessions only |
| Catalog |
Product Description |
Kit QTY per Month 1-20 |
Kit QTY per Month 21-49 |
Kit QTY per Month 50-75 |
Kit QTY per Month >75 | |||||
| 12013798 | Platelia SARS-CoV-2 Total Ab 480 tests | [***] | [***] | [***] | [***] |
Proposal and pricing set forth above is valid for thirty (30) days pending acceptance and counter-signature of this agreement. Term of this agreement is (36) thirty-six months from the Effective Date. Monthly kit volumes will be reviewed on a quarterly basis and pricing may be subject to increase for noncompliance.
Supplier may immediately terminate this Agreement in the event (a) Customer fails to make payment when due (b) materially breaches this Agreement (other than non-payment) and fails to cure such breach within thirty (30) days of notice by Supplier of such breach, or (c) Customer makes an assignment for the benefit of creditors or proceedings are commenced by or for Customer under any bankruptcy, insolvency, or debtor’s relief law.
Due to the high demand in our Covid offerings our supply will be on allocation short term. We cannot always confirm a delivery date, yet Sales will contact you with further information.
In the U.S., the test has been authorized by the FDA under an EUA for use by authorized laboratories. The test has not been FDA cleared or approved. The test has been authorized only for the presence of total antibodies against SARS- CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
| BioDesix, Inc.: | SUPPLER: | |||||||
| By: | /s/ Xxxxx Xxxxx |
By: | /s/ Xxxxx X. Xxxxx | |||||
| Name: | Xxxxx Xxxxx |
Name: | Xxxxx X. Xxxxx | |||||
|
Title: |
CFO |
Title: | Contract Analyst CDG Commercial Contract Management | |||||
| Date: | 5/14/2020 |
Date: | 05-12-20 | |||||
